in-PharmaTechnologist presents its round-up of the latest movers and shakers within the pharmaceutical industry, with news from Actelion, PhRMA, and Rx-360.
Jean-Pierre Garnier has become chairman of Actelion’s board of directors.
Garnier also serves on the board of the United Technologies Corporation and Renault S.A, and is Chairman of NormOxys.
He replaces Robert Cawthorn, who will remain in his current role until the Swiss firm’s 2012 annual general meeting.
Garnier said: "I look forward to guiding the company in the next phase of its growth together with my fellow Board members, management and all the Actelion employees."
The Pharmaceutical Research and Manufacturers of America (PhRMA) has drafted James Hoyes and Daniel Tasse to its board of directors.
Hoyes’ latest appointment comes shortly after he took on the role of president at EMD Serono, where he was previously chief commercial officer.
Ikaria chairman and CEO Tasse is also a member of the Healthcare Leadership Council and the board of directors of the Roundtable on Critical Care Policy.
PhRMA president and CEO John J. Castellani said of their appointments: "Their broad knowledge of the biopharmaceutical research sector will be instrumental in our continual efforts to promote patient-centered policies that support medical innovation. “
Analytical instrumentation makers Mustard Tree Instruments has promoted Brian Garrett to the role of chief technical officer.
Garrett, who joined the company as director of analytics two years ago, is now responsible for algorithm development and intellectual property acquisition.
Software developer Jared Peterson has also been promoted to become software architect and manager. He will lead the company’s software development team.
The business hopes the new appointments will bolster its development of new analytical tools to redefine product testing regimen and avoid costly recalls.
In a shakeup of its board of directors, Rx-360 has inked three year contracts with nine new members.
The team are Takeda’s Janice Berman, Heike Falkenhagen of Boehringer Ingelheim, BASF project manager Hubertus Folttmann, Jaspret Gill from Baxter, Pfizer’s Brian Johnson, Patrica Latzo of Mylan, Elizabeth Pileggi of Teva, Merck’s Swroop Sahota, and Melissa Seymour of Biogen Idec.
The new members join Rx-360 – formed in 2009 in the pursuit of enhancing quality and authenticity throughout the supply chain – in time for the launch of two new best practice documents addressing the issue of prevent cargo thefts and creating standards for tamper evident seals.
Craig Tooman has joined InSite Vision’s board of directors.
The founder and principal of Stockbourne LLC, which deals in strategic business and financial advisory services, has over 23 years experience in finance and investor relations for pharmaceutical companies.
“Having worked with Craig previously at both ILEX Oncology and Pharmacia, I look forward to his involvement with the company and his guidance as we chart our path forward as an emerging leader in the global ophthalmology market,” said Timothy Ruane, InSite Vision CEO.